Kemp Dolliver
Stock Analyst at Brookline Capital
(0.45)
# 4,247
Out of 5,139 analysts
17
Total ratings
30.77%
Success rate
-18.47%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals | Upgrades: Buy | $17 | $7.26 | +134.16% | 3 | Dec 18, 2025 | |
| RNTX Rein Therapeutics | Downgrades: Hold | n/a | $1.21 | - | 1 | Aug 19, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $5.14 | +250.19% | 1 | Jul 21, 2025 | |
| LSTA Lisata Therapeutics | Maintains: Buy | $20 → $32 | $2.16 | +1,381.48% | 1 | Jul 15, 2025 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $2.20 | +63.64% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $1.93 | +1,765.28% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $0.55 | +5,648.81% | 1 | Jan 25, 2024 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $64.25 | +55.64% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $1.46 | +3,804.11% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $2.74 | +812.41% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $7.14 | +162.61% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.65 | +1,130.77% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.68 | +730.88% | 1 | Feb 2, 2022 |
Verrica Pharmaceuticals
Dec 18, 2025
Upgrades: Buy
Price Target: $17
Current: $7.26
Upside: +134.16%
Rein Therapeutics
Aug 19, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.21
Upside: -
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $5.14
Upside: +250.19%
Lisata Therapeutics
Jul 15, 2025
Maintains: Buy
Price Target: $20 → $32
Current: $2.16
Upside: +1,381.48%
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $2.20
Upside: +63.64%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $1.93
Upside: +1,765.28%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $0.55
Upside: +5,648.81%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $64.25
Upside: +55.64%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $1.46
Upside: +3,804.11%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.74
Upside: +812.41%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $7.14
Upside: +162.61%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.65
Upside: +1,130.77%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.68
Upside: +730.88%